-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Hunan Kelun Pharmaceutical has entered the administrative approval stage for the inhalation ipratropium bromide solution reported as a generic type 4 product.
If it is successfully approved, it will become Kelun Pharmaceutical's first approved inhaler
.
According to data from Minet.
com, in 2021, the sales volume of terminal ipratropium bromide inhalers in Chinese public medical institutions will be close to 1 billion yuan, a year-on-year increase of more than 30%
.
If it is successfully approved, it will become Kelun Pharmaceutical's first approved inhaler
.
According to data from Minet.
com, in 2021, the sales volume of terminal ipratropium bromide inhalers in Chinese public medical institutions will be close to 1 billion yuan, a year-on-year increase of more than 30%
.
Source: State Food and Drug Administration official website
Ipratropium bromide is a highly selective M receptor blocker with strong bronchial smooth muscle relaxation, suitable for maintenance treatment of bronchospasm caused by chronic obstructive pulmonary disease , including chronic bronchitis and pulmonary Emphysema,
etc.
etc.
Currently available ipratropium bromide preparations in China include ipratropium bromide inhalation solution and ipratropium bromide aerosol
.
According to data from Minet.
com, in 2021, the sales volume of terminal ipratropium bromide inhalers in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 1 billion yuan, a year-on-year increase of 35.
19%.
, the original manufacturer Boehringer Ingelheim dominates the market, but due to the impact of generic drugs, the market share has a downward trend
.
.
According to data from Minet.
com, in 2021, the sales volume of terminal ipratropium bromide inhalers in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 1 billion yuan, a year-on-year increase of 35.
19%.
, the original manufacturer Boehringer Ingelheim dominates the market, but due to the impact of generic drugs, the market share has a downward trend
.
Sales of terminal ipratropium bromide inhalers in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Ipratropium bromide inhalation was included in the fifth batch of centralized procurement, and 4 pharmaceutical companies, Renhe Yikang, Jianjianyuan, Sipu Ruite, and Wuhan Xianlu Medicine , were selected
.
With the implementation of centralized procurement, the market pattern of ipratropium bromide inhalation will be reshuffled
.
.
With the implementation of centralized procurement, the market pattern of ipratropium bromide inhalation will be reshuffled
.
Inhalants that have been reported by Kelun Pharmaceuticals
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
According to the data from Minet.
com, in the field of inhalants, Kelun Pharmaceutical has submitted 4 applications for listing under the new registration classification.
Among them, ipratropium bromide solution for inhalation has entered the stage of administrative approval and is expected to become the company's first approved inhaler.
agent
.
com, in the field of inhalants, Kelun Pharmaceutical has submitted 4 applications for listing under the new registration classification.
Among them, ipratropium bromide solution for inhalation has entered the stage of administrative approval and is expected to become the company's first approved inhaler.
agent
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Note: The statistics are as of May 5, if there are any omissions, please correct me!
Recently, Hunan Kelun Pharmaceutical has entered the administrative approval stage for the inhalation ipratropium bromide solution reported as a generic type 4 product.
If it is successfully approved, it will become Kelun Pharmaceutical's first approved inhaler
.
According to data from Minet.
com, in 2021, the sales volume of terminal ipratropium bromide inhalers in Chinese public medical institutions will be close to 1 billion yuan, a year-on-year increase of more than 30%
.
If it is successfully approved, it will become Kelun Pharmaceutical's first approved inhaler
.
According to data from Minet.
com, in 2021, the sales volume of terminal ipratropium bromide inhalers in Chinese public medical institutions will be close to 1 billion yuan, a year-on-year increase of more than 30%
.
Source: State Food and Drug Administration official website
Ipratropium bromide is a highly selective M receptor blocker with strong bronchial smooth muscle relaxation, suitable for maintenance treatment of bronchospasm caused by chronic obstructive pulmonary disease , including chronic bronchitis and pulmonary Emphysema,
etc.
etc.
Currently available ipratropium bromide preparations in China include ipratropium bromide inhalation solution and ipratropium bromide aerosol
.
According to data from Minet.
com, in 2021, the sales volume of terminal ipratropium bromide inhalers in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 1 billion yuan, a year-on-year increase of 35.
19%.
, the original manufacturer Boehringer Ingelheim dominates the market, but due to the impact of generic drugs, the market share has a downward trend
.
.
According to data from Minet.
com, in 2021, the sales volume of terminal ipratropium bromide inhalers in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 1 billion yuan, a year-on-year increase of 35.
19%.
, the original manufacturer Boehringer Ingelheim dominates the market, but due to the impact of generic drugs, the market share has a downward trend
.
Sales of terminal ipratropium bromide inhalers in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Ipratropium bromide inhalation was included in the fifth batch of centralized procurement, and 4 pharmaceutical companies, Renhe Yikang, Jianjianyuan, Sipu Ruite, and Wuhan Xianlu Medicine , were selected
.
With the implementation of centralized procurement, the market pattern of ipratropium bromide inhalation will be reshuffled
.
.
With the implementation of centralized procurement, the market pattern of ipratropium bromide inhalation will be reshuffled
.
Inhalants that have been reported by Kelun Pharmaceuticals
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
According to the data from Minet.
com, in the field of inhalants, Kelun Pharmaceutical has submitted 4 applications for listing under the new registration classification.
Among them, ipratropium bromide solution for inhalation has entered the stage of administrative approval and is expected to become the company's first approved inhaler.
agent
.
com, in the field of inhalants, Kelun Pharmaceutical has submitted 4 applications for listing under the new registration classification.
Among them, ipratropium bromide solution for inhalation has entered the stage of administrative approval and is expected to become the company's first approved inhaler.
agent
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Note: The statistics are as of May 5, if there are any omissions, please correct me!
Recently, Hunan Kelun Pharmaceutical has entered the administrative approval stage for the inhalation ipratropium bromide solution reported as a generic type 4 product.
If it is successfully approved, it will become Kelun Pharmaceutical's first approved inhaler
.
According to data from Minet.
com, in 2021, the sales volume of terminal ipratropium bromide inhalers in Chinese public medical institutions will be close to 1 billion yuan, a year-on-year increase of more than 30%
.
If it is successfully approved, it will become Kelun Pharmaceutical's first approved inhaler
.
According to data from Minet.
com, in 2021, the sales volume of terminal ipratropium bromide inhalers in Chinese public medical institutions will be close to 1 billion yuan, a year-on-year increase of more than 30%
.
Source: State Food and Drug Administration official website
Ipratropium bromide is a highly selective M receptor blocker with strong bronchial smooth muscle relaxation, suitable for maintenance treatment of bronchospasm caused by chronic obstructive pulmonary disease , including chronic bronchitis and pulmonary Emphysema,
etc.
disease disease diseaseetc.
Currently available ipratropium bromide preparations in China include ipratropium bromide inhalation solution and ipratropium bromide aerosol
.
According to data from Minet.
com, in 2021, the sales volume of terminal ipratropium bromide inhalers in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 1 billion yuan, a year-on-year increase of 35.
19%.
, the original manufacturer Boehringer Ingelheim dominates the market, but due to the impact of generic drugs, the market share has a downward trend
.
hospital hospital hospital.
According to data from Minet.
com, in 2021, the sales volume of terminal ipratropium bromide inhalers in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will be close to 1 billion yuan, a year-on-year increase of 35.
19%.
, the original manufacturer Boehringer Ingelheim dominates the market, but due to the impact of generic drugs, the market share has a downward trend
.
Sales of terminal ipratropium bromide inhalers in Chinese public medical institutions (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
Ipratropium bromide inhalation was included in the fifth batch of centralized procurement, and 4 pharmaceutical companies, Renhe Yikang, Jianjianyuan, Sipu Ruite, and Wuhan Xianlu Medicine , were selected
.
With the implementation of centralized procurement, the market pattern of ipratropium bromide inhalation will be reshuffled
.
health , health, health , medicine , medicine, medicine.
With the implementation of centralized procurement, the market pattern of ipratropium bromide inhalation will be reshuffled
.
Inhalants that have been reported by Kelun Pharmaceuticals
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
According to the data from Minet.
com, in the field of inhalants, Kelun Pharmaceutical has submitted 4 applications for listing under the new registration classification.
Among them, ipratropium bromide solution for inhalation has entered the stage of administrative approval and is expected to become the company's first approved inhaler.
agent
.
com, in the field of inhalants, Kelun Pharmaceutical has submitted 4 applications for listing under the new registration classification.
Among them, ipratropium bromide solution for inhalation has entered the stage of administrative approval and is expected to become the company's first approved inhaler.
agent
.
Source: Minet database, the official website of the State Food and Drug Administration, etc.
Note: The statistics are as of May 5, if there are any omissions, please correct me!
